Form 4: Cadrenal CEO Sells Shares Under 10b5-1 Plan

Cadrenal Therapeutics CEO and Chairman, Quang X. Pham, reported the sale of 9,371 shares of common stock in late September 2025 under a pre-arranged trading plan.

Summary

• Quang X. Pham, who serves as CEO, Chairman, Director, and a 10% owner of Cadrenal Therapeutics, Inc. (CVKD), reported sales of the company's common stock.
• On September 24, 2025, 2,581 shares were sold at a price of $13.99 per share.
• On September 25, 2025, an additional 6,790 shares were sold at a weighted average price of $14.09 per share, with individual transaction prices ranging from $13.99 to $14.14.
• These transactions were executed pursuant to a Rule 10b5-1(c) trading plan, indicating they were pre-scheduled.
• Following these sales, Pham directly beneficially owns 203,933 shares of common stock.
• Pham also indirectly beneficially owns 200,000 shares through The PVBQ Living Trust, where he acts as the trustee and has sole voting and disposition power.

Sentiment

Score: 4

Explanation: The sale of shares by a key insider, even under a 10b5-1 plan, generally carries a slightly negative sentiment as it reduces management's direct stake in the company. However, the pre-planned nature mitigates some of the immediate negative implications of an unplanned sale.

Negatives

• The CEO, Chairman, and 10% owner sold a total of 9,371 shares of company common stock.
• Insider sales, even when conducted under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects.

Risks

• Potential negative market perception due to insider selling, which could exert downward pressure on the stock price.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Industry Context

Insider sales, particularly by high-ranking executives and significant shareholders, are closely watched by the market as they can signal management's perspective on the company's valuation or future prospects. While sales under a Rule 10b5-1 plan are pre-scheduled and designed to avoid accusations of insider trading, they still represent a reduction in insider ownership.

Comparison to Industry Standards

• Not applicable as this filing reports individual insider transactions rather than company performance metrics that can be benchmarked against industry peers.

Corporate Governance

Related Party Transactions

• Quang Pham is the Trustee of The PVBQ Living Trust, which indirectly owns 200,000 shares, and his child is the sole beneficiary. This represents a related party holding.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal regarding the company's future prospects, potentially influencing their investment decisions.
• Employees: No direct impact mentioned, but general market sentiment can affect employee morale and the perceived value of stock-based compensation.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company.

Key Dates

Recommendation

While insider selling by the CEO and Chairman is generally a negative signal, the execution under a Rule 10b5-1 plan suggests a pre-planned divestment rather than an immediate reaction to new negative information. The amount sold is also a relatively small portion of the total beneficial ownership (9,371 shares out of 403,933 total beneficial shares). Investors should monitor future filings and company performance, but this single event, while noteworthy, does not warrant an immediate 'sell' recommendation without further context or additional negative developments. A 'hold' position is prudent to observe further developments.

Keywords

Cadrenal Therapeutics, CVKD, Insider Sale, Form 4, Quang Pham, CEO, Director, 10b5-1 Plan, Stock Transaction, Beneficial Ownership